. Marduel, Human Mutations. Mutation in Brief, 2010.

. Bruckert, Consensus Cardio pour le praticien, 2009.

. Kumar, Robbins and Cotran. Pathologic Basis of Disease. 2009. 18. fhcanada.net, 2014.

S. Young, Recent progress in understanding apolipoprotein B, 1990.

A. Sahekar and G. Watts, New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes, 2013.

,. Parhofer-k and . Mipomersen, evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia, 2012.

A. Elis, R. Zhou, and A. Stein, Effect of lipid-lowering treatment on natural histroy of heterozygous familial hypercholesterolemia inp past three decades, 2011.

G. Thompson, , 2010.

R. Barkowski and W. Frishman, HDL metabolism and CETP inhibition, 2008.

J. Cohen, E. Boerwinkle, T. Mosley, and H. Hobbs, Sequence variations in PCSK9, low LDL, and protection against coronary heart disease, 2006.

. S. Sanofi and . Com, , p.29, 2013.

, Advances in Antisense Oligonucleotide Development for Target Identification, Validation, and as Novel Therapeutics. Melendez., Moizza Mansoor and Alirio J. s.l. : Gene Regulation and Systems Biology, vol.2, p.2733095, 2008.

M. Koziolkiewicz, E. Gendaszewska, and M. Maszweska, The mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothiote oligonucleotides depends upon the activity of an ecto-5'-nucleotidase, 2001.

. Exiqon, The structure of LNA?, 2016.

J. Kurreck, E. Wyszko, C. Gillen, and V. A. Erdmann, Design of antisens oligonucleotides stabilized by locked nucleic acides, 2002.

M. Frieden, H. F. Hansen, and T. Koch, Nuclease stability of LNA oligonucleotides and LNADNA chimeras, Nucleosides Nucleotides Nucleic acids, 2003.

. Huynh and . Vu-manh, , 2008.

E. E. Com, , 2016.

C. Hélène, Ester Saison-Behmoaras. ipubli.inserm.fr, 1994.

K. Vivek, P. Sharma, A. K. Rungta, and . Prasad, Nucleic acid therapeutics: basic concepts and recent developments, 2014.

R. D. Jager, L. P. Aiello, S. C. Patel, and E. T. Cunningham, Risks of intravitreous injection: a comprehensive review, Retina, vol.24, p.5, 2004.

A. E. Fung, P. J. Rosenfeld, and E. Reichel, The International Intravitreal Bevcizumab Safety Survey: using the internet to assess drug safety worldwide, Ophthalmol, vol.90, p.11, 2006.

J. T. Mendell and E. N. Olson, MicroRNAs in stress signaling and human disease, Cell, p.148, 2012.

E. Van-rooij, Introduction to the series on microRNAs in the cardiovascular system, Circ Res, p.110, 2012.

E. Van-rooij and E. N. Olson, MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles, Nat Rev Drug Discov, p.11, 2012.

J. Stenvang, A. Petri, M. Lindow, S. Obad, and S. Kauppinen, Inhibition of microRNA function by antimiR oligonucleotides, Silence, p.3, 2012.

S. B. Thorsen, S. Obad, N. F. Jensen, J. Stenvang, and S. Kauppinen, The therapeutic potential of microRNAs in cancer, p.18, 2012.

V. Ambros, The functions of animal microRNAs, Nature, p.431, 2004.

D. P. Bartel, MicroRNAs: target recognition and regulatory functions, Nature, vol.136, 2009.

S. Eva-van-rooij and . Kauppinen, EMBO Molecular Medicine., juin, vol.16, 2014.

F. R. Miravirsen-;-luca, M. A. Gebert, . Rebhan, E. M. Silvia, R. Crivelli et al., SPC3649) can inhibit the biogenesis of miR-122, vol.42, pp.609-621, 2013.

. Schmidt and F. Marco, Drug target miRNAs: chances and challenges. Cambridge : s.n, 2014.

M. Lindow and S. Kauppinen, Discovering the first microRNA-targeted drug, Cell biol, 2012.

D. Rader, J. Cohen, and H. Hobbs, Monogenic hypercholesreolemia : new insights in pathogenesis and treatment, 2003.

R. M. Crooke, M. J. Graham, and K. M. Lemonidis, An apolipoprotein B antisense

R. M. Crooke, B. F. Baker, and M. K. Wedel, Cardiovascular therapeutic applications, 2007.

G. Corp, KYNAMRO ® (mipomersen sodium) injection prescribing information, 2014.

C. Gelsinger, T. Steinhagen, and U. Kassner, Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia, 2012.

. Powell, , 1987.

E. Maartje, J. L. Visser, . Witztum, S. G. Erik, . Stroes et al., Antisense oligonucleotides for the treatment of dyslipidaemia, 2012.

R. S. Geary, Antisense oligonucleotide pharmacokinetics and metabolism, 2009.
DOI : 10.1517/17425250902877680

P. Kohli and C. P. Cannon, Dr Frank Bennett. A new approach to managing the 'statin-intolerant' patient?, 2012.

R. Z. Yu, T. W. Kim, and A. Hong, Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100, 2007.

A. A. Levin, R. Z. Yu, and R. S. Geary, Basic principles of the pharmacokinetics of antisense oligonucleotide drugs, 2007.

R. S. Geary, R. Z. Yu, and A. Siwkowski, Pharmacokinetic/pharmacodynamic properties of phosphorothioate 2?-O-(2-methoxyethyl)-modified antisense oligonucleotides in animal and man, 2007.

R. Z. Yu, K. M. Lemonidis, and M. J. Graham, Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B100, 2009.

S. T. Crooke and R. S. Geary, Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B, 2013.

M. Baek, R. Z. Yu, H. Gaus, J. S. Grundy, and R. S. Geary, In vitro metabolic stabilities and metabolism of 2?-O-(methoxyethyl) partially modified phosphorothioate antisense oligonucleotides in reincubated rat or human whole liver homogenates, 2010.

R. Yu, R. Geary, J. Flaim, G. Riley, D. Tribble et al., Lack of pharmacokinetic interaction of ISIS 301012, a 2'-Omethoxyethyl modified antisenseoligonucleotide targeting apoB-100 mRNA, with oral lipid lowering agents, simvastatin and ezetimibe, when coadministered in healthy humansubjects, 2009.

R. Z. Yu, R. S. Geary, and J. D. Flaim, Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2?-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe, when coadministered in healthy human subjects, 2009.

K. Hovingh, J. B. Kastelein, and J. J. , Efficacy and safety of mipomersen sodium (Kynamro)

Z. Li, M. L. Hard, and J. S. Grundy, Lack of clinical pharmacodynamic and pharmacokinetic drug-drug interactions between warfarin and the antisense oligonucleotide mipomersen, 2014.
DOI : 10.1097/fjc.0000000000000101

G. Corp, Kynamro pharmacology review, 2012.

S. P. Henry, Toxicologic Properties of 2'-O-Methoxyethyl Chimeric Antisense Inhibitors in Animals and Man, 2008.

, Genzyme corp. Kynamro, prescribing information, 2015.

R. Santos, P. Duell, C. East, J. Guyton, P. Moriarty et al., Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolamia: 2 year interm results of an open-label extension, 2013.

G. Corp, Kynamro (mipomersen sodium) injection, solution. 2013. 80.-. Product Information, 2013.

. Genzyme, R. Kynamro, . Evaluation, and . Mitigation-strategy,

C. Gagne, D. Gaudet, and E. Bruckurt, Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous hypercholeterolemia, 2002.

S. Walji, C. Neuwirth, and G. Thompson, Lipoprotein apheresis for the treatment of familial hypercholeterolemia, 2013.

R. Vishwanath and L. Hemphill, Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering, 2014.

M. Cassagnol, D. Ezzo, and P. Patel, New therapeutic alternatives for the managmeent of dyslipidemia, 2013.

, Cited: Novembre 30, 2015.] www.medicalletter.org. 88. committee for medicinal products for human use. ema.europa.eu, vol.21, 2013.

G. Visser-wagener, B. F. Baker, R. S. Geary, J. M. Donovan, U. H. Beuers et al.,

, apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial, 2012.

. Genzyme, Tertiary Pharmacology/Toxicology Review, 2012.

M. Visser, J. Witztum, E. Stroes, and J. Kastelein, Antisense oligonucleotides for the treatment of dyslipidemia, 2012.

J. J. Kastelein, M. Wedel, and B. Baker, Potent reduction of apoliporotein B and low density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apopliportein B

A. Mullick, W. Fu, and M. Graham, Antisense oligonucleotide reduction of apoB ameliorated artherosclerosis in LDL receptor-deficient mice, 2011.

C. Bennett and E. Swayze, RNA targeting therapeutics: molecular mechanism of antisense oligonucleotides as a therapeutic platform, 2010.

F. Akdim, E. Stroes, and J. J. Kastelein, Antisense apolipoprotein B therapy : where do we stand?, 2007.

R. Mckay, L. Miraglia, L. Cummins, S. Owens, H. Sasmor et al., Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase Calpha expression, 1999.

R. Yu, H. Zhang, and R. Geary, Pharmacokinetics and pharmacodynamics of an antisense phosphorothiote oligonucleotide targeting FasmRNA in mice, 2001.

R. Crooke, Antisense oligonucleotide as tyherapeutics for hyperlipidemia, 2005.

A. Goldberg, Novel therapies and new targets of treatment for familial hypercholesterolemia, 2010.

, ISIS Pharm. isispharm.com, 2015.

, Chemistry & biology

A. Dwaine, . Braasch, R. David, and . Corey, , vol.1, 2001.

, Concentration-Response Effect of Multiple Apo B Antisense Oligonucleotides on the Levels of Apo B mRNA after 24 Hr in HepG2

, Effect of Murine ApoB and MTP ASO Treatment on Hepatic Endoplasmic Reticulum Stress and Heat Shock Proteins